




FILLCHOICE[®] LUNG

Closed System Drug-Transfer Device



PATENT PENDING

FillChoice® Lung - CSTD

Ready-to-Transfer Closed System Transfer Device (CSTD) with Smart Pressure Equalisation system for hazardous drug reconstitution and safe handling.

FillChoice® Lung cutting-edge closed system transfer device (CSTD) without filters, compliant with the NIOSH protocols and definitions. FillChoice® Lung is a patented needle-free and filter-free system, filled with a sterile air for pressure equalisation, designed to be suitable for different vial sizes and a standard luer-lock syringe.

Safe and secure. FillChoice® Lung was designed to prevent the exposure of healthcare professionals to harmful and cytotoxic drugs during compounding and delivery to the patients in need.

Closed Circuit. FillChoice® Lung is a completely closed-system circuit with safe-sealed connections that ensures the preparation of medicine according to the medical prescription in conditions of maximum safety for healthcare professionals.

Needle-Free. Thanks to the proprietary Needle-free Injection Port - NIP®, FillChoice® Lung provides a completely hermetic and totally safe needle-free connections to the components of the system, that prevent accidental drug release.

Filter-Free. FillChoice® Lung is based on the pressure equalisation within the system itself, that guarantees safe, easy and efficient handling of the device, excluding the risk of wet filters and accidental drug vapor release.

Easy-To-Use. The linear pre-bonded closed-circuit system significantly reduces the time for reconstitution and administration, while the proprietary know-how and hermetic connections save healthcare practitioners from extra steps and device manipulations.



Bibliography

- NIOSH. *A Performance Test Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs*. Docket Number 288-A, CDC-2016-0090.
- Centres for Disease Control and Prevention. *Workplace safety and health: Chemotherapy drug exposures at an oncology clinic—Florida*. June 2012. Atlanta, GA: CDC; 2012.
- Oncology Nursing Society. *Safe handling of hazardous drugs*. In: Polovich M, editor. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011.
- USP General Chapter <800>: *Hazardous Drugs – Handling in Healthcare Settings*.
- USP Chapter <1207>: *Container Closure Integrity Testing*.
- OSHA Technical Manual *Controlling occupational exposure to hazardous drugs*. Section VI, Chapter 2. Washington, DC: United States Department of Labor; 1999.
- Controlled Environment Testing Association. *CETA compounding isolator testing guide*, CAG-002-2006. Revised December 8, 2008. Raleigh, NC: CETA; 2008.





Haemopharm.it



HAEMOPHARM HEALTHCARE S.R.L.

COMMERCIAL OFFICE

Viale Lazio, 26

I - 20135 Milano (MI)

Phone +39 02 5513513

Fax +39 02 55191982

info@haemopharm.it

haemopharm.it



PAOLO GOBBI FRATTINI S.R.L.

FACTORY

I - 23030 Tovo di Sant'Agata (SO)

Via Provinciale, 8

Tel +39 0342 771017

Fax +39 0342 771018

info@haemopharm.it

haemopharm.it

All the information contained in this document and the described product can be changed at any moment by Haemopharm Healthcare without notice. The information about the specific product in use is contained exclusively on the product packaging. FillChoice® LUNG is a proprietary patented system and registered trademark of Paolo Gobbi Frattini S.r.l. © 2022 Paolo Gobbi Frattini s.r.l. All rights reserved. REV. 04/2022-en.